KADCYLA TRASTUZUMAB EMTANSINE
USPTO Trademark Record · Serial No. 85163890
Trademark details
It was initially claimed by GENENTECH, INC. on 20101028.
That brand applies to the following goods and services:Pharmaceutical preparations containing trastuzumab emtansine for treatment of cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, angiogenesis diseases and disorders, ocular diseases and disorders, inflammatory diseases and disorders, gastro-intestinal diseases and disorders, respiratory diseases and disorders, neurological diseases and disorders, infectious diseases and disorders, metabolic diseases and disorders, Providing educational training in the medical field, Medical services.
You can learn more about that trademark on the USPTO website: View the USPTO record
Services available
Questions about this trademark?
If you have questions or issues related to the KADCYLA TRASTUZUMAB EMTANSINE trademark — or to trademarks in general — our trademark attorneys can help. No appointment needed: call us or request a free estimate.
Register a Trademark Get a Free Estimate
